Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05166733
Other study ID # 2021(ke)CL274
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date December 2021
Est. completion date December 31, 2022

Study information

Verified date December 2021
Source The First People's Hospital of Changzhou
Contact Jie Cao
Phone 13646125766
Email mayday509@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To explore the differences in the green channel process of stroke in various regions of the same province, to target and shorten the time delay of emergency process, and to explore the key technologies of endovascular treatment of acute ischemic stroke. To investigate the use and embolectomy effect of Reco, the first embolectomy stent in China, in economically developed areas. Health economic assessment (cost-benefit analysis) of ischemic stroke patients in various regions of the province.


Description:

The Reco Embolectomy Stent is indicated for patients who cannot be treated with intravenous tissue activator (IVt-PA) or who have failed IVt-PA therapy and is intended to remove thrombus from a large intracranial vessel in patients with ischemic stroke to restore blood flow.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 300
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient age =18 years - The clinical diagnosis was acute ischemic stroke - Large vascular lesions were detected by head CT, CTA, MRI, MRA or DSA - Preoperative baseline NIHSS score > 4 - MRS 0-1 before this stroke - Mechanical thrombectomy was performed - Use Reco thrombectomy bracket Exclusion Criteria: - epileptic seizure - Sudden coma - Neurological loss symptoms quickly improved - Imaging was negative, but clinical symptoms did not rule out subarachnoid hemorrhage - Previous intracranial hemorrhage, subarachnoid hemorrhage, and brain tumor (with mass effect) - History of head trauma within 3 months prior to surgery - History of arterial puncture with difficulty in compression and hemostasis within one week prior to surgery - Physical examination revealed evidence of active bleeding or trauma (e.g. fracture) - Women are known to be pregnant or breastfeeding - Severe allergies to contrast agents are known

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China The First People's Hospital of Changzhou Changzhou Jiangsu

Sponsors (6)

Lead Sponsor Collaborator
PengYa Jingjiang People's Hospital, Northern Jiangsu Province People's Hospital, The Affiliated Hospital of Xuzhou Medical University, The Second Hospital of Nanjing Medical University, Yixing People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The time between the onset of the disease and the opening of the blood vessels Calculate the time from onset to vessel opening Immediately after surgery
Primary Functional independence at 90 days (defined as mRS=2) mRS scores were performed 90 days after surgery 90day after surgery
Primary Symptomatic intracranial hemorrhage within 24 hours after surgery Symptomatic intracranial hemorrhage was evaluated by CT 24 hours after operation 24 hours after surgery
Secondary Time from onset to admission Calculate the time from onset to admission Immediately after surgery
Secondary Time from admission and puncture time Calculate the time from onset to admission Immediately after surgery
Secondary Puncture to the time of vessel opening Calculate the time from puncture to vascular opening Immediately after surgery
See also
  Status Clinical Trial Phase
Completed NCT01642056 - EPI-743 for Metabolism or Mitochondrial Disorders Phase 1/Phase 2
Completed NCT01212419 - SWC on aEEG in Post-surgical Neonates on Morphine and Midazolam N/A
Terminated NCT04763603 - Assessment of Plaque Vulnerability Using a Novel Technique: Multi-spectral PhotoAcoustic Imaging.
Recruiting NCT05539196 - A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
Not yet recruiting NCT05089786 - Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001) N/A
Completed NCT00296140 - Implementing Evidence in the Detection and Treatment of Post Stroke Depression N/A
Completed NCT04660019 - Combined Scalp and Ear Acupuncture in Patients With Proton Pump Inhibitor- Dependent Gastroesophageal Reflux Disease N/A